William Grossman has been appointed chief medical officer of Bellicum Pharmaceuticals (NASDAQ: [[ticker:BLCM]]). Grossman comes to the Houston biotech company from Genentech, where he was group medical director, cancer immunotherapy. Bellicum develops immunotherapies for cancers and blood disorders. In January, the company disclosed that the FDA halted a clinical trial testing its lead drug, BPX-501, after three patients in the study developed brain injuries.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
